BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31455365)

  • 41. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
    Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
    Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.
    Fan J; Wu J; Huang B; Zhu Y; Shi H; Dai X; Nie X
    Diagn Pathol; 2020 May; 15(1):42. PubMed ID: 32375829
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
    Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
    Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
    Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
    Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship of radiometabolic biomarkers to KRAS mutation status and ALK rearrangements in cases of lung adenocarcinoma.
    Aras G; Kanmaz ZD; Tuncay E; Çetinkaya E; Yentürk E; Kocatürk C; Öz B; Çermik TF; Purisa S
    Tumori; 2019 Dec; 105(6):501-508. PubMed ID: 31910789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Anaplastic lymphoma kinase-positive adenocarcinoma of lung: a cytopathologic analysis].
    Chen Y; Gao L; Wang Y; Gui X; Zhang H; Wang L; Gu L; Feng L; Wu J; Yang W; Song Y; Zeng H; Zhang J; Bai Q; Zhou X; Ping B
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):628-32. PubMed ID: 26705277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement.
    Nakajima N; Yoshizawa A; Kondo K; Rokutan-Kurata M; Hirata M; Furuhata A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Fujimoto M; Date H; Haga H
    Histopathology; 2017 Jul; 71(1):143-149. PubMed ID: 28231386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
    Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
    Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.
    Jeong CJ; Lee HY; Han J; Jeong JY; Lee KS; Choi YL; Choi JY
    Clin Nucl Med; 2015 Jan; 40(1):e34-9. PubMed ID: 25243942
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells.
    Baldi L; Mengoli MC; Bisagni A; Banzi MC; Boni C; Rossi G
    Lung Cancer; 2014 Nov; 86(2):291-5. PubMed ID: 25312989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
    Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G
    Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
    Koh Y; Kim DW; Kim TM; Lee SH; Jeon YK; Chung DH; Kim YW; Heo DS; Kim WH; Bang YJ
    J Thorac Oncol; 2011 May; 6(5):905-12. PubMed ID: 21358343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
    BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
    Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
    J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 58. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
    Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
    Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anaplastic lymphoma kinase expression in small-cell lung cancer.
    Kondoh C; Horio Y; Hayashi Y; Ebi H; Hida T; Hasegawa Y; Yatabe Y
    Histopathology; 2019 Jul; 75(1):20-28. PubMed ID: 30790327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.